First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors. Kim TW, Burris HA, de Miguel Luken MJ, Pishvaian MJ, et al. Clin Cancer Res 2022;28:3452-3463.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kim TW, Burris HA, de Miguel Luken MJ, Pishvaian MJ, et al. First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors. Clin Cancer Res 2022;28:3452-3463.
PMID: 35699599